地高辛与去乙基胺碘酮相互作用的人群药代动力学分析
该研究基于368例房颤合并心衰患者的地高辛人群药代动力学分析,发现去乙基胺碘酮浓度和肌酐清除率影响地高辛清除率。模拟显示合用胺碘酮时0.125 mg/d毒性风险高,推荐根据肾功能和去乙基胺碘酮浓度调整剂量。
要点
- 去乙基胺碘酮浓度每增加100 ng/mL,地高辛清除率降低3%。
- 肌酐清除率倍增时地高辛清除率增加21%。
- 合用胺碘酮时推荐日剂量0.0625 mg(CLcr>30 mL/min)。
核心结论
- 肾功能损害和高血浆去乙基胺碘酮浓度会降低房颤合并心衰患者的地高辛清除率。
研究设计与样本
- 人群药代动力学分析,纳入368例口服地高辛患者共3288个数据点,其中48例(13%)合用胺碘酮。
- 采用一室模型一级吸收,以胺碘酮或去乙基胺碘酮作为时变协变量,通过逐步向前纳入和向后剔除构建模型。
- 用蒙特卡洛模拟评估地高辛浓度在毒性范围(≥0.9 ng/mL)的患者比例。
主要发现
- 地高辛血清浓度中位数为0.75 ng/mL,胺碘酮和去乙基胺碘酮血浆浓度中位数分别为610和644 ng/mL。
- 地高辛口服清除率最终模型由肌酐清除率和去乙基胺碘酮浓度解释。
- 肌酐清除率倍增时地高辛清除率增加21%,去乙基胺碘酮浓度增加100 ng/mL时清除率降低3%。
- 模拟显示合用胺碘酮患者中日剂量0.125 mg时毒性范围比例高。
关键数值与推荐
- 肌酐清除率>30 mL/min的患者推荐地高辛日剂量0.0625 mg。
- 肌酐清除率≤30 mL/min且去乙基胺碘酮浓度>600 ng/mL的患者推荐日剂量0.03125 mg。
临床怎么用
- 房颤合并心衰患者合用地高辛与胺碘酮时,应参考肌酐清除率和去乙基胺碘酮浓度调整地高辛剂量。
- 肌酐清除率>30 mL/min者建议日剂量0.0625 mg,避免0.125 mg/d。
- 肌酐清除率≤30 mL/min且去乙基胺碘酮浓度>600 ng/mL者建议日剂量0.03125 mg。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To evaluate the effects of amiodarone and/or N-desethylamiodarone concentrations on digoxin pharmacokinetics and determine the optimal dose of digoxin combined with amiodarone in Japanese patients with atrial fibrillation and heart failure. METHODS: A population pharmacokinetic analysis of 3288 points from 368 patients receiving oral digoxin, including 48 (13%) who were coadministered amiodarone, was performed. A 1-compartment model with first-order absorption with amiodarone or N-desethylamiodarone as time-varying covariates for apparent digoxin clearance was constructed using stepwise forward inclusion and backward elimination approaches. The percentage of patients with digoxin values in the toxic range (≥0.9 ng/mL) was evaluated with Monte Carlo simulation. RESULTS: The median serum digoxin concentration was 0.75 ng/mL; the median plasma concentrations of amiodarone and N-desethylamiodarone were 610 and 644 ng/mL, respectively. The final model for oral clearance of digoxin was explained by creatinine clearance (CLcr) and the N-desethylamiodarone concentration. Digoxin clearance increased by 21% when CLcr was doubled and decreased by 3% when the N-desethylamiodarone concentration increased by 100 ng/mL. In the simulation, the proportion of patients with values in the toxic range was high at 0.125 mg daily among patients taking amiodarone. A daily dose of 0.0625 mg is recommended for patients with a CLcr >30 mL/min. For patients with a CLcr ≤30 mL/min and an N-desethylamiodarone concentration >600 ng/mL, a daily dose of 0.03125 mg is recommended because of reduced digoxin clearance. CONCLUSIONS: This study revealed that renal impairment and high plasma N-desethylamiodarone concentrations reduce digoxin clearance in patients with atrial fibrillation and heart failure.
引用
- Hirai T, Kasai H, Shiga T, et al. Population pharmacokinetic analysis of the interaction of digoxin with N-desethylamiodarone in patients with atrial fibrillation and heart failure. Br J Clin Pharmacol. 2025. PMID: 40289268. doi:10.1002/bcp.70075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。